Encompass Health Co. (NYSE:EHC) Shares Sold by Park Avenue Securities LLC

Park Avenue Securities LLC lowered its stake in shares of Encompass Health Co. (NYSE:EHC) by 2.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,430 shares of the company’s stock after selling 148 shares during the quarter. Park Avenue Securities LLC’s holdings in Encompass Health were worth $448,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. TD Asset Management Inc increased its holdings in shares of Encompass Health by 239.6% in the fourth quarter. TD Asset Management Inc now owns 1,969,186 shares of the company’s stock valued at $131,384,000 after purchasing an additional 1,389,275 shares during the period. 8 Knots Management LLC purchased a new position in Encompass Health during the 4th quarter worth $75,424,000. Norges Bank acquired a new stake in shares of Encompass Health in the 4th quarter worth $69,178,000. Epoch Investment Partners Inc. boosted its holdings in shares of Encompass Health by 102.9% in the fourth quarter. Epoch Investment Partners Inc. now owns 1,399,341 shares of the company’s stock valued at $93,364,000 after acquiring an additional 709,593 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Encompass Health by 379.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 578,349 shares of the company’s stock worth $38,587,000 after acquiring an additional 457,796 shares during the period. Institutional investors and hedge funds own 97.25% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on EHC. Stephens restated an “overweight” rating and set a $94.00 target price on shares of Encompass Health in a research report on Wednesday, June 5th. Royal Bank of Canada upped their target price on shares of Encompass Health from $83.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 22nd. Raymond James restated a “strong-buy” rating and issued a $95.00 price target (up previously from $85.00) on shares of Encompass Health in a report on Friday, April 26th. Mizuho lifted their price objective on Encompass Health from $93.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Finally, Barclays raised their price target on Encompass Health from $101.00 to $108.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $93.29.

Insider Transactions at Encompass Health

In related news, CEO Mark J. Tarr sold 44,976 shares of Encompass Health stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total value of $3,745,151.52. Following the transaction, the chief executive officer now owns 554,098 shares in the company, valued at $46,139,740.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Encompass Health news, CEO Mark J. Tarr sold 44,976 shares of Encompass Health stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the transaction, the chief executive officer now directly owns 554,098 shares of the company’s stock, valued at $46,139,740.46. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Elissa Joy Charbonneau sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $85.02, for a total transaction of $850,200.00. Following the sale, the insider now owns 18,594 shares of the company’s stock, valued at $1,580,861.88. The disclosure for this sale can be found here. Insiders sold a total of 69,519 shares of company stock worth $5,816,091 in the last ninety days. Insiders own 2.10% of the company’s stock.

Encompass Health Trading Down 0.1 %

Shares of Encompass Health stock opened at $85.79 on Friday. Encompass Health Co. has a fifty-two week low of $57.55 and a fifty-two week high of $87.94. The business’s fifty day moving average is $84.77 and its two-hundred day moving average is $77.51. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.14. The firm has a market cap of $8.64 billion, a PE ratio of 23.19, a P/E/G ratio of 1.34 and a beta of 0.90.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.93 by $0.19. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The company had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter in the previous year, the business earned $0.88 EPS. The firm’s revenue was up 13.4% on a year-over-year basis. Analysts anticipate that Encompass Health Co. will post 4.1 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Monday, July 1st will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Monday, July 1st. This represents a $0.60 annualized dividend and a dividend yield of 0.70%. Encompass Health’s dividend payout ratio is presently 16.22%.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.